BR0316489A - Composições e formulações de gastrina e métodos para uso e preparação - Google Patents

Composições e formulações de gastrina e métodos para uso e preparação

Info

Publication number
BR0316489A
BR0316489A BR0316489-6A BR0316489A BR0316489A BR 0316489 A BR0316489 A BR 0316489A BR 0316489 A BR0316489 A BR 0316489A BR 0316489 A BR0316489 A BR 0316489A
Authority
BR
Brazil
Prior art keywords
seq
residues
gastrin
amino acid
formulations
Prior art date
Application number
BR0316489-6A
Other languages
English (en)
Inventor
Antonio Cruz
Original Assignee
Waratah Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Waratah Pharmaceuticals Inc filed Critical Waratah Pharmaceuticals Inc
Publication of BR0316489A publication Critical patent/BR0316489A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2207—Gastrins; Cholecystokinins [CCK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"COMPOSIçõES E FORMULAçõES DE GASTRINA E MéTODOS PARA USO E PREPARAçãO". Uma modalidade da invenção proporcionada aqui é uma composição farmacêutica compreendendo um composto de gastrina tendo uma atividade prolongada quando administrada a um indivíduo em comparação à gastrina nativa. São proporcionados métodos de conjugação de partes da seq³ência de aminoácidos da gastrina tendo capacidade funcional para se ligar ao receptor de gastrina/CCK, a varias porções veículo, incluindo o uso de regiões espaçadoras de aminoácidos e uso de reagentes de ligação reticulada bifuncionais. Métodos de tratamento de um paciente com diabetes com as composições são proporcionados.
BR0316489-6A 2002-11-21 2003-11-21 Composições e formulações de gastrina e métodos para uso e preparação BR0316489A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US42810002P 2002-11-21 2002-11-21
US42856202P 2002-11-22 2002-11-22
US43059002P 2002-12-03 2002-12-03
US51993303P 2003-11-14 2003-11-14
PCT/CA2003/001778 WO2004045640A1 (en) 2002-11-21 2003-11-21 Gastrin compositions and formulations, and methods of use and preparation

Publications (1)

Publication Number Publication Date
BR0316489A true BR0316489A (pt) 2005-10-11

Family

ID=32330051

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0316489-6A BR0316489A (pt) 2002-11-21 2003-11-21 Composições e formulações de gastrina e métodos para uso e preparação

Country Status (14)

Country Link
US (3) US20040266682A1 (pt)
EP (3) EP1837031B1 (pt)
JP (2) JP2006513719A (pt)
KR (1) KR20050083933A (pt)
AT (1) ATE378065T1 (pt)
AU (1) AU2003285229C1 (pt)
BR (1) BR0316489A (pt)
CA (1) CA2505167A1 (pt)
DE (1) DE60317554T2 (pt)
DK (1) DK1565212T3 (pt)
MX (1) MXPA05005330A (pt)
NO (1) NO20053027L (pt)
PL (1) PL376622A1 (pt)
WO (1) WO2004045640A1 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6558952B1 (en) * 1992-12-14 2003-05-06 Waratah Pharmaceuticals, Inc. Treatment for diabetes
GB9409496D0 (en) * 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
CN1486204A (zh) 2001-01-12 2004-03-31 ������˹ҩƷ��˾ 用于胰岛再生的含胃泌素/cck受体配基及egf受体配基的组合物
EP1372717A2 (en) 2001-03-23 2004-01-02 Aphton Corporation Combination treatment of pancreatic cancer
US20090191232A1 (en) 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
US7037504B2 (en) * 2001-10-23 2006-05-02 Waratah Pharmaceuticals, Inc. Epidermal growth factor protein and gene, and methods of use therefor
CA2494134A1 (en) * 2002-05-24 2003-12-04 Waratah Pharmaceuticals, Inc. Treatment for diabetes
EP1837031B1 (en) 2002-06-07 2009-10-14 Waratah Pharmaceuticals, Inc. Compositions and methods for treating diabetes
DE60316798T2 (de) 2002-06-07 2008-07-24 Waratah Pharmaceuticals, Inc., Toronto Zusammensetzungen und verfahren zur behandlung von diabetes
US20040229810A1 (en) * 2002-10-22 2004-11-18 Antonio Cruz Gastrin compositions and formulations, and methods of use and preparation
EP1608984A2 (en) * 2003-03-28 2005-12-28 Aphton Corporation Gastrin hormone immunoassays
US20080039379A1 (en) * 2003-05-27 2008-02-14 Waratah Pharmaceuticals, Inc. Compositions Comprising Gastrin Compounds and Their Use in Diabetes
CA2554458A1 (en) * 2004-01-30 2005-08-11 Waratah Pharmaceuticals, Inc. The combined use of glp-1 agonists and gastrin for regulating blood glucose levels
US20090117102A1 (en) * 2004-07-01 2009-05-07 Antonio Cruz Methods and compositions using CD3 agonists
CA2580965C (en) 2004-09-22 2014-04-08 Receptor Biologix, Inc. Monoclonal antibodies to progastrin
BRPI0616949A2 (pt) * 2005-10-07 2011-07-05 Waratah Pharmaceuticals Inc composição farmacêutica, uso de uma composição, e, kit
WO2009043519A2 (en) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
CA2699067A1 (en) * 2007-09-11 2009-04-09 Dorian Bevec Use of rfrp, alone or in combination with neurokinin-b, as a therapeutic agent
EP2413694A4 (en) * 2009-04-03 2014-02-26 Univ Toledo PEG-ALBUMIN COMPOSITION HAVING AT LEAST ONE PROTECTED THIOL REGION AS A PLATFORM FOR MEDICAMENTS
KR101286721B1 (ko) 2009-06-05 2013-07-16 한국과학기술연구원 폴리-시스테인 펩티드 융합 재조합 알부민 및 이의 제조방법
WO2011131646A1 (en) * 2010-04-20 2011-10-27 Novo Nordisk A/S Long-acting gastrin derivatives
EA023925B1 (ru) 2010-04-27 2016-07-29 Зилэнд Фарма А/С Пептидные конъюгаты агонистов рецептора glp-1 и их применение
CN102260868A (zh) * 2011-07-22 2011-11-30 上海交通大学 高耐蚀性钝化液及其生产工艺
US9259477B2 (en) 2011-11-03 2016-02-16 Zealand Pharma A/S GLP-1 receptor agonist peptide gastrin conjugates
US20140309175A1 (en) * 2012-03-16 2014-10-16 Belrose Pharma, Inc. Polymeric conjugates of c1-inhibitors
MX2016005556A (es) 2013-11-06 2016-07-15 Zealand Pharma As Compuestos agonistas duales de gip-glp-1 y procedimientos.
WO2015067716A1 (en) 2013-11-06 2015-05-14 Zealand Pharma A/S Glucagon-glp-1-gip triple agonist compounds
US10253078B2 (en) 2014-10-29 2019-04-09 Zealand Pharma A/S GIP agonist compounds and methods
PE20191083A1 (es) 2016-12-09 2019-08-20 Zealand Pharma As Agonistas duales acilados de glp-1/glp-2
JP7469225B2 (ja) 2017-06-15 2024-04-16 キャンサー アドヴァンシーズ インク． 腫瘍及び癌に対する体液性及び細胞性免疫を誘発するための組成物及び方法
WO2019023295A1 (en) * 2017-07-27 2019-01-31 Saint Louis University HUMAN EPIDERMAL GROWTH FACTOR MODIFIED BY FATTY ACID
US11434291B2 (en) 2019-05-14 2022-09-06 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
CA3182445A1 (en) 2020-06-11 2021-12-16 Francisco Leon Methods and compositions for preventing type 1 diabetes

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464363A (en) 1979-12-20 1984-08-07 Merck & Co., Inc. Ajuvants for rectal delivery of drug substances
JPS6028994A (ja) 1983-07-08 1985-02-14 Wakunaga Seiyaku Kk 〔２１―ロイシン〕ヒトウロガストロン
US4686283A (en) 1985-04-16 1987-08-11 Syntex (U.S.A.) Inc. Analogs of transforming and epidermal growth factor fragments for therapy and diagnosis
EP0284898A3 (de) 1987-04-02 1990-06-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Hinge-Peptid, Verfahren zu seiner Herstellung und seine Verwendung zur Herstellung synthetischer Immunogene
ATE114160T1 (de) * 1989-01-24 1994-12-15 Aphton Corp Immunogenische zusammensetzungen gegen gastrin- peptide.
US5023077A (en) 1989-01-24 1991-06-11 Aphton Corporation Immunogenic compositions and methods for the treatment and prevention of gastric and duodenal ulcer disease
US4997950A (en) * 1989-04-20 1991-03-05 Richard Finbar Murphy Novel C-terminal gastrin antagonists
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US6267964B1 (en) 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
IE68593B1 (en) 1989-12-06 1996-06-26 Sanofi Sa Heterocyclic substituted acylaminothiazoles their preparation and pharmaceutical compositions containing them
ATE196548T1 (de) 1991-05-10 2000-10-15 Genentech Inc Auswählen von agonisten und antagonisten von liganden
WO1993003757A1 (en) 1991-08-16 1993-03-04 Chiron Corporation Muteins of epidermal growth factor exhibiting enhanced binding at low ph
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6558952B1 (en) 1992-12-14 2003-05-06 Waratah Pharmaceuticals, Inc. Treatment for diabetes
US5885956A (en) 1992-12-14 1999-03-23 Research Triangle Pharmaceuticals Treatment for diabetes using a gastrin/CCK receptor ligand and an EGF receptor ligand
ATE222503T1 (de) * 1994-01-24 2002-09-15 Waratah Pharmaceuticals Inc Behandlung von diabetes
WO1995029690A1 (en) 1994-04-29 1995-11-09 The Trustees Of The University Of Pennsylvania Biologically active peptides and methods of identifying the same
GB9409496D0 (en) 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
DE19514087A1 (de) 1995-04-13 1996-10-17 Deutsches Krebsforsch Konjugat aus einem Wirkstoff, einem Polyether und ggfs. einem nicht als körperfremd angesehenen, nativen Protein
WO1999045026A1 (en) 1998-03-05 1999-09-10 Chiron Corporation Method for increasing the serum half-life of a biologically active molecule
US20040037818A1 (en) 1998-07-30 2004-02-26 Brand Stephen J. Treatment for diabetes
US6420339B1 (en) * 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
AU2153500A (en) 1998-11-19 2000-06-05 Millennium Pharmaceuticals, Inc. Egf-like nucleic acids and polypeptides and uses thereof
PT1180121E (pt) 1999-05-17 2004-03-31 Conjuchem Inc Peptidos insulinotropicos de longa duracao
AU778929B2 (en) 1999-12-06 2004-12-23 General Hospital Corporation, The Pancreatic stem cells and their use in transplantation
AU3350201A (en) 2000-02-18 2001-08-27 Inst Medical W & E Hall Pancreatic islet cell growth factors
JP2004509079A (ja) 2000-08-02 2004-03-25 セラテクノロジーズ・インコーポレーテッド 効力が増大した修飾生体ペプチド
CN1486204A (zh) 2001-01-12 2004-03-31 ������˹ҩƷ��˾ 用于胰岛再生的含胃泌素/cck受体配基及egf受体配基的组合物
WO2002079457A1 (en) 2001-03-29 2002-10-10 Ixion Biotechnology, Inc. Method for transdifferentiation of non-pancreatic stem cells to the pancreatic differentiation pathway
CN1169827C (zh) 2001-08-07 2004-10-06 沈阳三生制药股份有限公司 一种增强多肽在体内稳定性药物的生产方法及其应用
US7037504B2 (en) 2001-10-23 2006-05-02 Waratah Pharmaceuticals, Inc. Epidermal growth factor protein and gene, and methods of use therefor
CA2494134A1 (en) 2002-05-24 2003-12-04 Waratah Pharmaceuticals, Inc. Treatment for diabetes
DE60316798T2 (de) 2002-06-07 2008-07-24 Waratah Pharmaceuticals, Inc., Toronto Zusammensetzungen und verfahren zur behandlung von diabetes
EP1837031B1 (en) 2002-06-07 2009-10-14 Waratah Pharmaceuticals, Inc. Compositions and methods for treating diabetes
US20040229810A1 (en) 2002-10-22 2004-11-18 Antonio Cruz Gastrin compositions and formulations, and methods of use and preparation
AU2003283004A1 (en) 2002-10-22 2004-05-13 Waratah Pharmaceuticals, Inc. Treatment of diabetes
AU2004233911A1 (en) 2003-04-30 2004-11-11 Waratah Pharmaceuticals, Inc. Combined use of keratinocyte growth factor agonists and gastrin compounds
CA2527186A1 (en) 2003-05-27 2004-12-09 Waratah Pharmaceuticals, Inc. Compositions comprising gastrin compounds and their use in diabetes
CA2554458A1 (en) 2004-01-30 2005-08-11 Waratah Pharmaceuticals, Inc. The combined use of glp-1 agonists and gastrin for regulating blood glucose levels
US20090117102A1 (en) 2004-07-01 2009-05-07 Antonio Cruz Methods and compositions using CD3 agonists
BRPI0616949A2 (pt) 2005-10-07 2011-07-05 Waratah Pharmaceuticals Inc composição farmacêutica, uso de uma composição, e, kit
WO2007062531A1 (en) 2005-12-02 2007-06-07 Waratah Pharmaceuticals, Inc. Combination treatments with gastrin agonists for diabetes and related diseases
WO2007095737A1 (en) 2006-02-21 2007-08-30 Waratah Pharmaceuticals Inc. Combination therapy for the treatment of diabetes comprising an exendin agonist and a gastrin compound

Also Published As

Publication number Publication date
JP2010265294A (ja) 2010-11-25
EP1884247A3 (en) 2008-02-13
AU2003285229B2 (en) 2009-07-30
JP2006513719A (ja) 2006-04-27
US7803766B2 (en) 2010-09-28
DE60317554D1 (de) 2007-12-27
PL376622A1 (pl) 2006-01-09
US20040266682A1 (en) 2004-12-30
ATE378065T1 (de) 2007-11-15
NO20053027L (no) 2005-08-22
EP1565212A1 (en) 2005-08-24
EP1837031A1 (en) 2007-09-26
AU2003285229C1 (en) 2010-04-01
CA2505167A1 (en) 2004-06-03
AU2003285229A1 (en) 2004-06-15
KR20050083933A (ko) 2005-08-26
NO20053027D0 (no) 2005-06-20
EP1884247A2 (en) 2008-02-06
MXPA05005330A (es) 2005-10-26
EP1565212B1 (en) 2007-11-14
US20110034379A1 (en) 2011-02-10
DE60317554T2 (de) 2008-09-18
US20090075873A1 (en) 2009-03-19
DK1565212T3 (da) 2008-02-25
EP1837031B1 (en) 2009-10-14
WO2004045640A1 (en) 2004-06-03

Similar Documents

Publication Publication Date Title
BR0316489A (pt) Composições e formulações de gastrina e métodos para uso e preparação
HK1119955A1 (en) Modified kunitz domain polypeptide
CA2291963A1 (en) Tumor necrosis factor receptor-derived peptide analogues
BRPI0511421A (pt) composições cosmética e farmacêutica para tratar materiais contendo queratina, uso de composições cosméticas, molécula efetora que liga queratina, uso da mesma, e, processo
DK165988B (da) Modificerede egliner b og c, deres anvendelse som proteaseinhibitorer, fremgangsmaade til fremstilling deraf samt farmaceutiske praeparater indeholdende de modificerede egliner b og c
DE59007517D1 (de) Neue proteine mit tnf-hemmender wirkung und ihre herstellung.
CA2439598C (en) Modified derivatives of cck-8
AU2002238701A1 (en) Modified derivatives of CCK-8
HENSCHEN Disulfide bridges in the middle part of human fibrinogen
Jensen et al. Cuticular proteins from the giant cockroach, Blaberus craniifer
JPH0222292A (ja) 高カルシウム体液性因子拮抗薬
Adermann et al. Isolation, characterization and synthesis of a novel pardaxin isoform
US7223835B2 (en) VEGF peptides and their use for inhibiting angiogenesis
AU2002210713A1 (en) VEGF peptides and their use for inhibiting angiogenesis
AU2865801A (en) Therapeutic peptides
Kimura et al. Amino acid sequence of chymotrypsin inhibitor ECI from the seeds of Erythrina variegata (Linn.) var. Orientalis
Seyer et al. Covalent structure of collagen: Amino acid sequence of three cyanogen bromide-derived peptides from human α1 (V) collagen chain
Carlquist Solid phase synthesis of a 31-residue fragment of human glucose-dependent insulinotropic polypeptide (GIP) by the continuous flow polyamide method
EP2298792A3 (en) Peptides targeted to protein kinase C isoforms and uses thereof
Ötvös et al. Coupling difficulty following replacement of Tyr with HOTic during synthesis of an analog of an EGF B‐loop fragment
ATE425988T1 (de) Peptide mit affinitat fur ein phospholipid und deren verwendung
MORODER et al. Studies on Immunoassays of Peptide Factors. II. Fluorescence Enzyme Immunoassay for Human Little-Gastrin
WO2002083729A3 (en) Polypeptides derived from amyloid precursor peptide (app) and their uses
Koubová et al. Desoctapeptideinsulin fragments formed by chymotryptic cleavage and suitable for modification of insulin in positions A 14 and B 16
Nakamaru et al. Purification and primary structure of four novel neuropeptides in Aplysia kwrodai

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]